SOLUTIONS FOR PATIENTS & PROVIDERS

Viventis is shaping the future of cancer treatment by integrating AI, genomic insights, and patient-centric care. Explore how our solutions are making a difference in oncology today.

FOR PATIENTS

Viventis is dedicated to empowering patients with personalized, AI-driven cancer care solutions. Our technology ensures tailored treatment strategies and access to cutting-edge therapies.

Personalized Treatment Plans: AI-driven insights help design individualized cancer treatment strategies for better outcomes.

Clinical Trial Matching with AI: Our platform connects patients with relevant clinical trials, increasing access to innovative therapies.

Support & Patient Resources: Comprehensive educational tools, support groups, and expert consultations help patients navigate their treatment journey with confidence.

FOR ONCOLOGISTS

Viventis enhances oncologists' capabilities with advanced AI-driven decision-making tools, streamlining treatment planning and improving patient care.

AI-Driven Treatment Recommendations: Our platform provides oncologists with real-time, data-backed treatment insights for precise cancer care.

Real-Time Genomic Insights: Advanced genomic analytics offer personalized insights, optimizing therapy selection for each patient.

Integration with Hospital Systems: Seamless compatibility with electronic health records (EHRs) and hospital management systems ensures effortless adoption and workflow enhancement.

FOR BIOPHARMA & RESEARCHERS

Viventis accelerates the pace of drug discovery and clinical research by leveraging AI and real-world oncology data.

Accelerated Drug Discovery: AI-powered analytics streamline target identification, drug formulation, and preclinical studies

Access to Real-World Oncology Data: Secure access to extensive patient data sets enhances research capabilities and drug development.

AI-Driven Clinical Trial Optimization: Our platform improves trial efficiency by identifying optimal patient cohorts, reducing dropout rates, and increasing trial success rates.